The rights issue was subscribed for approximately 87.0 percent with and without the support of unit rights, whereby the underwriting commitment from Flerie Invest AB was used for 1,438,755 units, corresponding to the remaining approximately 13.0 percent of the rights issue. The part of the issue relating to the underwriting commitment was allocated and registered with the Swedish Companies Registration Office in November. This means that during November, the number of shares in Nanologica has increased by 5,755,020 shares from 82,602,214 to 88,357,234 shares and that the share capital has increased by SEK 575,502.0 from SEK 8,260,221.4 to SEK 8,835,723.4.
 
The Extraordinary General Meeting on September 23, 2024, resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue (regarding the part where the share capital increase is attributable to a new issue of shares), with relevant adjustments to achieve an appropriate quota value. During November, Nanologica applied for permission from the Swedish Companies Registration Office for a reduction of the share capital by SEK 4,329,504.466, from SEK 8,835,723.4 to SEK 4,506,218.934. Subject to the Swedish Companies Registration Office’s approval which is expected in January at the earliest, the share’s quota value after the reduction will amount to SEK 0.051 per share.
 
As of November 29, 2024, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 88,357,234.